Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
| Datum | Name des Inhabers | Gehandelte Aktien | Wertspanne ($) | Transaktionstyp | Preisspanne ($) | Aktien am Meldungsende | % Veränderung |
|---|---|---|---|---|---|---|---|
| 2026-05-22 | Mr. Jonathan WygantVP & CAO | -24,00k | 494,42k | Derivative Exercise and Sale | 24,80 - 45,40 | 7,87k | - |
| 2026-05-20 | Dr. Robert S. EpsteinIndependent Chair | -10,00k | 440,13k | Automatic Disposition | 44,01 | 43,13k | -18,82% |
| 2026-05-06 | Ms. Annie McGuireExec. VP, General Counsel & Head of Market Access | -10,20k | 398,21k | Automatic Disposition | 38,05 - 40,00 | 1,13k | -90,02% |
| 2026-03-04 | Ms. Annie McGuireExec. VP, General Counsel & Head of Market Access | -6,66k | 236,72k | Automatic Disposition | 35,29 - 36,34 | 11,34k | -37,00% |
| 2026-03-04 | Ms. Rebecca ChambersExec. VP & CFO | -18,34k | 662,87k | Automatic Disposition | 35,55 - 36,33 | 36,20k | -33,63% |
| 2026-03-04 | Mr. Marc A. StapleyCEO & Director | -45,52k | 1,64M | Automatic Disposition | 35,56 - 36,28 | 143,90k | -24,03% |
| 2026-03-04 | Dr. John LeiteGlobal Chief Commercial Officer | -5,26k | 185,08k | Automatic Disposition | 35,19 | 18,38k | -22,25% |
| 2026-03-02 | Mr. Marc A. StapleyCEO & Director | -19,46k | 700,57k | Sale to Issuer | 36,01 | 189,42k | -9,31% |
| 2026-03-02 | Dr. Phillip G. FebboChief Scientific & Medical Officer | -13,43k | 485,43k | Automatic Disposition | 36,16 | 32,06k | -29,51% |
| 2026-03-02 | Dr. Phillip G. FebboChief Scientific & Medical Officer | -6,04k | 217,32k | Sale to Issuer | 36,01 | 32,06k | -15,84% |
| 2026-03-02 | Dr. John LeiteGlobal Chief Commercial Officer | -7,52k | 270,69k | Sale to Issuer | 36,01 | 23,64k | -24,13% |
| 2026-03-02 | Ms. Rebecca ChambersExec. VP & CFO | -7,23k | 260,50k | Sale to Issuer | 36,01 | 54,54k | -11,71% |
| 2026-03-02 | Ms. Annie McGuireExec. VP, General Counsel & Head of Market Access | -6,90k | 248,54k | Sale to Issuer | 36,01 | 17,99k | -27,72% |
| 2026-03-02 | Mr. Jonathan WygantVP & CAO | -3,01k | 108,25k | Sale to Issuer | 36,01 | 7,87k | -27,64% |
| 2026-02-26 | Dr. Phillip G. FebboChief Scientific & Medical Officer | -24,49k | 948,83k | Sale to Issuer | 38,75 | 39,67k | -38,17% |
| 2026-02-26 | Ms. Rebecca ChambersExec. VP & CFO | -12,05k | 466,90k | Sale to Issuer | 38,75 | 47,56k | -20,21% |
| 2026-02-26 | Dr. John LeiteGlobal Chief Commercial Officer | -8,91k | 345,07k | Sale to Issuer | 38,75 | 16,39k | -35,21% |
| 2026-02-26 | Mr. Marc A. StapleyCEO & Director | -35,84k | 1,39M | Sale to Issuer | 38,75 | 170,64k | -17,36% |
| 2026-02-26 | Ms. Annie McGuireExec. VP, General Counsel & Head of Market Access | -10,87k | 421,10k | Sale to Issuer | 38,75 | 11,34k | -48,94% |
| 2025-12-16 | Ms. Annie McGuireExec. VP, General Counsel & Head of Market Access | -10,74k | 463,20k | Automatic Disposition | 43,13 - 43,68 | 758,00 | -93,41% |
| 2025-12-05 | Ms. Karin EasthamIndependent Director | -20,00k | 753,52k | Derivative Exercise and Sale | 7,60 - 46,59 | 4,23k | - |
| 2025-12-04 | Mr. Marc A. StapleyCEO & Director | -7,67k | 361,08k | Automatic Disposition | 46,90 - 47,35 | 135,55k | -5,35% |
| 2025-12-02 | Mr. Marc A. StapleyCEO & Director | -7,91k | 365,31k | Sale to Issuer | 46,16 | 135,55k | -5,52% |
| 2025-12-02 | Dr. Phillip G. FebboChief Scientific & Medical Officer | -2,96k | 136,40k | Sale to Issuer | 46,16 | 16,29k | -15,36% |
| 2025-12-02 | Mr. Jonathan WygantVP & CAO | -1,33k | 61,16k | Sale to Issuer | 46,16 | 4,26k | -23,74% |
| 2025-12-04 | Ms. Rebecca ChambersExec. VP & CFO | -13,28k | 621,96k | Automatic Disposition | 46,61 - 47,25 | 36,20k | -26,84% |
| 2025-12-02 | Ms. Rebecca ChambersExec. VP & CFO | -3,38k | 156,21k | Sale to Issuer | 46,16 | 36,20k | -8,55% |
| 2025-12-04 | Ms. Annie McGuireExec. VP, General Counsel & Head of Market Access | -1,42k | 67,26k | Automatic Disposition | 47,10 - 47,51 | 11,50k | -11,01% |
| 2025-12-02 | Ms. Annie McGuireExec. VP, General Counsel & Head of Market Access | -3,05k | 140,88k | Sale to Issuer | 46,16 | 11,50k | -20,98% |
| 2025-12-04 | Dr. John LeiteGlobal Chief Commercial Officer | -1,28k | 60,72k | Automatic Disposition | 47,51 | 8,07k | -13,67% |
| 2025-12-02 | Dr. John LeiteGlobal Chief Commercial Officer | -2,90k | 133,86k | Sale to Issuer | 46,16 | 8,07k | -26,44% |
| 2025-11-25 | Dr. John LeiteGlobal Chief Commercial Officer | -2,81k | 140,40k | Automatic Disposition | 50,00 | 6,54k | -30,04% |
| 2025-11-25 | Mr. Evan JonesIndependent Director | -1,11k | 55,58k | Automatic Disposition | 50,25 | 20,04k | -5,23% |
| 2025-11-20 | Mr. Jens H. HolsteinIndependent Director | -10,00k | 423,56k | Automatic Disposition | 40,95 - 43,21 | 17,88k | -35,87% |
| 2025-11-07 | Mr. Jonathan WygantVP & CAO | -10,92k | 449,91k | Verkauf | 40,21 - 42,33 | 2,78k | -79,70% |
| 2025-11-05 | Ms. Annie McGuireExec. VP, General Counsel & Head of Market Access | -6,47k | 258,64k | Automatic Disposition | 40,00 | 9,96k | -39,36% |
| 2025-11-05 | Mr. Evan JonesIndependent Director | -30,00k | 1,13M | Derivative Exercise and Sale | 5,28 - 45,73 | 21,15k | - |
| 2025-11-05 | Mr. Evan JonesIndependent Director | -13,20k | 603,84k | Automatic Disposition | 45,73 - 46,38 | 21,15k | -38,42% |
| 2025-11-05 | Ms. Karin EasthamIndependent Director | -9,67k | 387,19k | Automatic Disposition | 40,02 | 4,23k | -69,56% |
| 2025-11-05 | Ms. Rebecca ChambersExec. VP & CFO | -7,00k | 287,00k | Automatic Disposition | 41,00 | 46,20k | -13,16% |
| 2025-10-06 | Dr. Phillip G. FebboChief Scientific & Medical Officer | -8,35k | 300,71k | Automatic Disposition | 36,02 | 13,43k | -38,34% |
| 2025-10-01 | Ms. Annie McGuireExec. VP, General Counsel & Head of Market Access | -2,16k | 75,61k | Automatic Disposition | 35,00 | 16,43k | -11,62% |
| 2025-10-01 | Dr. Robert S. EpsteinIndependent Chair | -10,00k | 271,37k | Derivative Exercise and Sale | 7,94 - 35,08 | 53,13k | - |
| 2025-10-01 | Dr. Robert S. EpsteinIndependent Chair | -11,47k | 402,44k | Automatic Disposition | 35,08 | 53,13k | -17,76% |
| 2025-10-01 | Dr. John LeiteGlobal Chief Commercial Officer | -2,54k | 88,87k | Automatic Disposition | 35,00 | 9,35k | -21,36% |
| 2025-09-19 | Ms. Annie McGuireExec. VP, General Counsel & Head of Market Access | -2,28k | 76,92k | Automatic Disposition | 33,69 | 18,59k | -10,94% |
| 2025-09-04 | Mr. Marc A. StapleyCEO & Director | -7,67k | 233,13k | Automatic Disposition | 30,41 | 135,55k | -5,35% |
| 2025-09-02 | Ms. Rebecca ChambersExec. VP & CFO | -5,37k | 161,72k | Sale to Issuer | 30,11 | 53,20k | -9,17% |
| 2025-09-02 | Ms. Annie McGuireExec. VP, General Counsel & Head of Market Access | -3,51k | 105,60k | Sale to Issuer | 30,11 | 20,87k | -14,39% |
| 2025-09-02 | Mr. Marc A. StapleyCEO & Director | -7,91k | 238,29k | Sale to Issuer | 30,11 | 143,22k | -5,24% |
| 2025-09-02 | Dr. Phillip G. FebboChief Scientific & Medical Officer | -2,96k | 88,98k | Sale to Issuer | 30,11 | 21,78k | -11,95% |
| 2025-09-02 | Dr. John LeiteGlobal Chief Commercial Officer | -2,90k | 87,38k | Sale to Issuer | 30,11 | 11,89k | -19,62% |
| 2025-09-02 | Mr. Jonathan WygantVP & CAO | -1,65k | 49,62k | Sale to Issuer | 30,11 | 13,70k | -10,74% |
| 2025-06-13 | Ms. Karin EasthamIndependent Director | -4,59k | 122,39k | Automatic Disposition | 26,66 | 13,91k | -24,81% |
| 2025-06-13 | Ms. Muna BhanjiIndependent Director | -4,59k | 122,37k | Automatic Disposition | 26,67 | 29,99k | -13,27% |
| 2025-06-04 | Dr. John LeiteGlobal Chief Commercial Officer | -2,81k | 76,41k | Automatic Disposition | 27,20 | 9,08k | -23,63% |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Mit E-Mail registrieren
Haben Sie schon ein Konto? Anmelden
Haben Sie kein Konto? Registrieren
Durch die Registrierung bestätige ich, dass ich die Allgemeinen Geschäftsbedingungen von ADVFN gelesen und verstanden habe und ihnen zustimme und dass ich ein Privatinvestor bin.
Premium
